Soligenix
Clinical trials sponsored by Soligenix, explained in plain language.
A biopharmaceutical company developing treatments for rare diseases and biodefense.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Can a new infusion tame the painful ulcers of Behcet's disease?
Disease control CompletedThis pilot study tests whether an experimental drug called dusquetide can reduce the number and pain of mouth and genital ulcers in people with Behcet's disease, an inflammatory condition. Participants receive the drug by intravenous infusion twice a week for four weeks, with fol…
Phase 2 • Sponsor: Soligenix • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Light-Activated gel shows promise for psoriasis in early trial
Disease control CompletedThis study tested a gel called SGX302, which is activated by visible light, on 15 people with mild-to-moderate plaque psoriasis. The goal was to see if it could clear or nearly clear skin lesions over 18 weeks. The treatment is applied to the skin and then exposed to light, aimin…
Phase 2 • Sponsor: Soligenix • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC